Clinical Trial Update: Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for QRX003 Lotion in Netherton Syndrome (Phase 2/Phase 3) focusing on safety, tolerability, and efficacy; the study is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Netherton Syndrome

Drugs mentioned

• QRX003 Lotion

Snippet

Sponsor: Quoin Pharmaceuticals | Conditions: Netherton Syndrome | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING